NZ789385A - Compositions and methods for treating tauopathies - Google Patents
Compositions and methods for treating tauopathiesInfo
- Publication number
- NZ789385A NZ789385A NZ789385A NZ78938517A NZ789385A NZ 789385 A NZ789385 A NZ 789385A NZ 789385 A NZ789385 A NZ 789385A NZ 78938517 A NZ78938517 A NZ 78938517A NZ 789385 A NZ789385 A NZ 789385A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- amino acid
- acid sequence
- disease
- human tau
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 208000005613 Tauopathy Diseases 0.000 title claims abstract description 37
- 108090001123 antibodies Proteins 0.000 claims abstract description 149
- 102000004965 antibodies Human genes 0.000 claims abstract description 149
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims abstract description 21
- 206010001897 Alzheimer's disease Diseases 0.000 claims abstract description 13
- 102100002485 MAPT Human genes 0.000 claims description 205
- 150000001413 amino acids Chemical class 0.000 claims description 76
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 201000011240 frontotemporal dementia Diseases 0.000 claims description 29
- 201000002242 tauopathy Diseases 0.000 claims description 25
- 206010012289 Dementia Diseases 0.000 claims description 24
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 11
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- 208000005145 Cerebral Amyloid Angiopathy Diseases 0.000 claims description 10
- 101710009640 IGKV1D-8 Proteins 0.000 claims description 9
- 101710024481 IGKV2-29 Proteins 0.000 claims description 9
- 101710009635 IGKV2D-26 Proteins 0.000 claims description 9
- 102100005978 IGKV3-20 Human genes 0.000 claims description 9
- 101710024987 IGKV3-20 Proteins 0.000 claims description 9
- 101710009651 IGKV3D-15 Proteins 0.000 claims description 9
- 239000000902 placebo Substances 0.000 claims description 8
- 229940068196 placebo Drugs 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 210000002682 Neurofibrillary Tangles Anatomy 0.000 claims description 7
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000008581 Brain Disease Diseases 0.000 claims description 6
- 206010014623 Encephalopathy Diseases 0.000 claims description 6
- 206010014625 Encephalopathy Diseases 0.000 claims description 6
- 206010015037 Epilepsy Diseases 0.000 claims description 6
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 6
- 206010018341 Gliosis Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- 208000005264 Motor Neuron Disease Diseases 0.000 claims description 6
- 206010028003 Motor neurone disease Diseases 0.000 claims description 6
- 102000030002 Prion Proteins Human genes 0.000 claims description 6
- 108091000054 Prion Proteins Proteins 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 230000001154 acute Effects 0.000 claims description 6
- 201000008319 inclusion body myositis Diseases 0.000 claims description 6
- 230000000750 progressive Effects 0.000 claims description 6
- 230000002739 subcortical Effects 0.000 claims description 6
- 208000006141 Amyloid angiopathy Diseases 0.000 claims description 5
- 210000000349 Chromosomes Anatomy 0.000 claims description 5
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 5
- 206010010254 Concussion Diseases 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 201000010374 Down syndrome Diseases 0.000 claims description 5
- 206010072075 Gerstmann Straussler Scheinker syndrome Diseases 0.000 claims description 5
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 5
- 102100008989 IGHV1-2 Human genes 0.000 claims description 5
- 101710003461 IGHV1-2 Proteins 0.000 claims description 5
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 5
- 208000001089 Multiple System Atrophy Diseases 0.000 claims description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 5
- 201000011585 Pick's disease Diseases 0.000 claims description 5
- 206010039911 Seizure Diseases 0.000 claims description 5
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 5
- 206010044688 Trisomy 21 Diseases 0.000 claims description 5
- 206010070976 Craniocerebral injury Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000000170 Postencephalitic Parkinson Disease Diseases 0.000 claims description 4
- 208000005765 Traumatic Brain Injury Diseases 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 3
- 102000033170 PRNP Human genes 0.000 claims description 3
- 101710024107 PRNP Proteins 0.000 claims description 3
- 208000002593 Pantothenate Kinase-Associated Neurodegeneration Diseases 0.000 claims description 3
- 208000003715 Parkinsonian Disorders Diseases 0.000 claims description 3
- 206010034010 Parkinsonism Diseases 0.000 claims description 3
- 229960003330 Pentetic Acid Drugs 0.000 claims description 3
- 230000002308 calcification Effects 0.000 claims description 3
- 230000000472 traumatic Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 108050005300 MDM4 Proteins 0.000 claims 1
- 206010056332 Panencephalitis Diseases 0.000 claims 1
- 102000001309 Proto-Oncogene Proteins c-mdm2 Human genes 0.000 claims 1
- 230000002490 cerebral Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 229920003253 poly(benzobisoxazole) Polymers 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 32
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 29
- 230000001603 reducing Effects 0.000 description 22
- 230000001629 suppression Effects 0.000 description 21
- 238000006722 reduction reaction Methods 0.000 description 20
- 210000003722 Extracellular Fluid Anatomy 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 102100002977 CDR1 Human genes 0.000 description 15
- 230000001965 increased Effects 0.000 description 14
- 210000002966 Serum Anatomy 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 210000004556 Brain Anatomy 0.000 description 9
- 230000001174 ascending Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000036231 pharmacokinetics Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 231100000494 adverse effect Toxicity 0.000 description 6
- 230000001580 bacterial Effects 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 230000003285 pharmacodynamic Effects 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000640 hydroxylating Effects 0.000 description 5
- 238000005805 hydroxylation reaction Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 229960001230 Asparagine Drugs 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000003834 intracellular Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000002569 neurons Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 230000035693 Fab Effects 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 210000004080 Milk Anatomy 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 230000002518 glial Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 229920000023 polynucleotide Polymers 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000001183 Brain Injury Diseases 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 102000028664 Microtubules Human genes 0.000 description 2
- 108091022031 Microtubules Proteins 0.000 description 2
- 210000004688 Microtubules Anatomy 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 229940068968 Polysorbate 80 Drugs 0.000 description 2
- 206010048327 Supranuclear palsy Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001508 asparagines Chemical class 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 230000035533 AUC Effects 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241001502578 Citrus variegation virus Species 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 210000001808 Exosomes Anatomy 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108090001095 Immunoglobulin G Proteins 0.000 description 1
- 102000004851 Immunoglobulin G Human genes 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 101710028108 MAPT Proteins 0.000 description 1
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 1
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 210000001322 Periplasm Anatomy 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101710005031 RMDN1 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 230000037218 TERMINAL ELIMINATION HALF-LIFE Effects 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000001724 coherent Stokes Raman spectroscopy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 108010031614 immunorphin Proteins 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003274 myotonic Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Abstract
Dosage regimens and formulations of anti-human tau antibodies are provided. These formulations and dosage regimens find use in the treatment of tauopathies such as progressive supranuclear palsy and Alzheimer's disease.
Description
COMPOSITIONS AND METHODS FOR TREATING TAUOPATHIES
Cross-Reference to Related Application
This application is a onal of New Zealand Application No. 759298, filed on 18
er 2019, and is related to International Patent Application No. ,
filed on 16 June 2017; each of which are orated herein by reference in their entirety.
Field
The present application relates generally to dosage regimens and ations for the
clinical use of anti-tau antibodies.
Background
Protein accumulation, modifications, and ation are pathological aspects of
numerous egenerative diseases. Pathologically modified and aggregated tau including
hyperphosphorylated tau conformers are an invariant hallmark of thies and correlate
with disease severity.
The microtubule associated protein tau is abundant in the central nervous system and
is produced primarily by neurons. Tau promotes the assembly of, maintains the structure of,
and stabilizes microtubules. The tau proteins are derived from alternative mRNA splice
variants that ate from a single gene and result in mature proteins that vary in size from
352 to 441 amino acids. While the fetal brain contains a single tau isoform (Tau-352), six tau
ms exist in the adult human brain. They differ from one another in having three or four
microtubule binding repeats of 31-32 amino acids each, and two, one, or no amino terminal
s of 29 amino acids each.
Tauopathies are a class of neurodegenerative diseases resulting from the pathological
aggregation of Tau protein in so-called neurofibrillary tangles (NFT) in the brain. Some
examples of tauopathies include progressive uclear palsy, Alzheimer's disease,
frontotemporal dementia (FTD), corticobasal degeneration, and frontotemporal lobar
degeneration.
There is a need in the art for methods of treating tauopathies. In order to treat the
growing numbers of patients with tauopathies, there is a need for a therapeutic antibody
against tau and appropriate dosage regimens and formulations for the clinical use of such an
uman tau antibody.
Summary
This disclosure relates, in part, to dosage regimens and formulations of anti-human
tau antibodies or tau-binding fragments thereof and their use in the treatment of a thy.
In one aspect, this disclosure es a method of treating a tauopathy in a human
subject in need thereof. The method involves administering to the human subject an antihuman
tau antibody at a fixed dose of 2000 mg. The anti-human tau antibody comprises an
[text continues on page 2]
immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain
variable region (VL). The VH comprises VH complementarity determining regions (VH-
CDRs), wherein VH-CDRI comprises or consists of the amino acid sequence of SEQ ID
N0216; VH-CDR2 comprises or ts of the amino acid ce of SEQ ID N017; and
VH—CDR3 comprises or consists of the amino acid sequence of SEQ ID N0118. The VL
comprises s, wherein VL-CDRI comprises or consists of the amino acid ce
of SEQ ID N0119; VL—CDR2 comprises or consists of the amino acid sequence of SEQ ID
NO:20; and VL-CDR3 comprises or consists of the amino acid sequence of SEQ ID N022].
In certain instances the anti-human tau dy is administered to the human subject
intravenously. In certain cases, the fixed dose of 2000 mg of the uman tau antibody is
administered once every four weeks.
In another aspect, provided herein is a method of treating a tauopathy in a human
subject in need thereof The method involves administering to the human subject an anti-
human tau antibody at a fixed dose of 150 mg. The anti—human tau dy comprises an
immunoglobulin heavy chain le region (VH) and an immunoglobulin light chain
variable region (VL). The VH comprises VH mentarity determining regions (VH-
CDRs), wherein VH-CDRI comprises or consists of the amino acid sequence of SEQ ID
N0116; VH—CDR2 comprises or consists of the amino acid sequence of SEQ ID N017; and
VH-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18. The VL
comprises VL-CDRs, wherein VL-CDRI comprises or ts of the amino acid sequence
of SEQ ID N0219; VL-CDR2 ses or consists of the amino acid sequence of SEQ ID
NO:20; and VL-CDR3 comprises or ts of the amino acid sequence of SEQ ID NO:21.
In certain instances the anti-human tau antibody is administered to the human subject
intravenously. In certain cases, the fixed dose of 150 mg of the anti-human tau antibody is
administered once every four weeks.
In another aspect, provided herein is a method of treating a tauopathy in a human
subject in need thereof. The method involves administering to the human subject an anti-
human tau antibody at a fixed dose of 210 mg. The anti-human tau antibody comprises an
immunoglobulin heavy chain le region (VH) and an immunoglobulin light chain
variable region (VL). The VH comprises VH complementarity determining regions (VH-
CDRs), wherein VH-CDRI comprises or consists of the amino acid sequence of SEQ ID
NO:16; VH—CDRZ comprises or consists of the amino acid sequence of SEQ ID N017; and
VH-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18. The VL
ses VL—CDRs, wherein VL-CDRI comprises or consists of the amino acid sequence
of SEQ ID NO:19; VL-CDR2 comprises or consists of the amino acid sequence of SEQ ID
NO:20; and VL-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:21.
In n instances the anti-human tau antibody is administered to the human subject
intravenously. In certain cases, the fixed dose of 210 mg of the anti-human tau antibody is
administered once every four weeks.
In another aspect, provided herein is a method of treating a tauopathy in a human
subject in need thereof. The method involves stering to the human subject an anti-
human tau antibody at a fixed dose of 2100 mg. The anti-human tau antibody comprises an
immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain
variable region (VL). The VH comprises VH complementarity determining s (VH-
CDRs), wherein VH-CDRI comprises or consists of the amino acid sequence of SEQ ID
N0116; VH—CDRZ comprises or ts of the amino acid sequence of SEQ ID NO:17; and
VH-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18. The VL
comprises VL-CDRs, wherein VL-CDRl comprises or ts of the amino acid sequence
of SEQ ID NO:19; VL-CDR2 ses or consists of the amino acid ce of SEQ ID
NO:20; and VL-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:21.
In certain instances the anti-human tau antibody is administered to the human subject
intravenously. In certain cases, the fixed dose of 2100 mg of the anti-human tau antibody is
stered once every four weeks.
In one aspect, provided herein is a method of treating a tauopathy in a human subject
in need thereof. The method involves administering to the human subject an uman tau
dy at a fixed dose of 4200 mg. The anti-human tau antibody comprises an
immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain
variable region (VL). The VH comprises VH complementarity determining regions (VH-
CDRs), wherein VH-CDRl comprises or consists of the amino acid sequence of SEQ ID
NO: 16; 2 comprises or consists of the amino acid sequence of SEQ ID N017; and
VH-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:18. The VL
comprises VL-CDRs, wherein VL-CDRI comprises or consists of the amino acid sequence
of SEQ ID NO:19; VL-CDR2 comprises or ts of the amino acid sequence of SEQ ID
NO:20; and VL-CDR3 comprises or consists of the amino acid sequence of SEQ ID NO:21.
In certain instances the anti-human tau antibody is administered to the human subject
intravenously. In certain cases, the fixed dose of 4200 mg of the anti-human tau dy is
administered once every four weeks.
The following ments apply to all of the above aspects. In some instances, the
tauopathy is ssive supranuclear palsy, Alzheimer’s disease, amyotrophic lateral
sclerosis/parkinsonism— dementia complex, argyrophilic grain dementia, British type amyloid
angiopathy, cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt- Jakob
e, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's
me, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism
linked to chromosome 17, frontotemporal lobar degeneration, Gerstmann-Straussler—
Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, multiple system
atrophy, ic dystrophy, Niemann-Pick disease type C, non-Guamanian motor neuron
disease with neurofibrillary s, Pick's disease, postencephalitic sonism, prion
protein cerebral amyloid angiopathy, progressive subcortical gliosis, globular glial tauopathy,
subacute sclerosing panencephalitis, Tangle only dementia, multi-infarct dementia, stroke,
chronic traumatic encephalopathy, traumatic brain injury, sion, seizures, epilepsy, or
acute lead encephalopathy. In one instance, the tauopathy is progressive supranuclear palsy.
In another ce, the tauopathy is Alzheimer’s disease. In certain cases, the VH of the
anti-human tau antibody comprises or consists of SEQ ID NO: 12, and the VL of the anti-
human tau antibody comprises or ts of SEQ ID NO: 13. In certain instances, the anti-
human tau dy comprises a heavy chain and a light chain, wherein the heavy chain
comprises or consists of SEQ ID N014, and the light chain comprises or consists of SEQ ID
NO:15.
In another aspect, this disclosure features a ceutical composition comprising
an uman tau antibody. The pharmaceutical ition comprises an anti-human tau
antibody at a concentration of 50 mg/ml or 60 mg/ml, histidine at a concentration of 20 mM,
sucrose at a concentration of 250 mM, polysorbate—80 at a concentration of 0.05% (w/v). In
some instances, the pharmaceutical composition further comprises 50 uM diethylenetnamine
pentaacetic acid (DTPA). The anti-human tau antibody comprises a VH and a VL. The VH
comprises a VH-CDRl sing or consisting of the amino acid sequence of SEQ ID
NO:16, a VH-CDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:17,
and a VH-CDR3 comprising or consisting of the amino acid sequence of SEQ ID NO: 18. The
VL ses a l comprising or consisting of the amino acid sequence of SEQ ID
N0219, a VL-CDR2 comprising or consisting of the amino acid sequence of SEQ ID NO:20;
and a VL-CDR3 comprising or consisting of the amino acid sequence of SEQ ID NO:21. The
pharmaceutical composition has a pH of 6.0.
In some embodiments, the VH of the anti-human tau antibody comprises or consists
of SEQ ID NO: 12 and the VL of the anti-human tau antibody comprises or ts of SEQ
ID NO: 13. In some embodiments, the anti-human tau antibody comprises a heavy chain and
a light chain, wherein the heavy chain comprises or consists of SEQ ID NO:14 and the light
chain comprises or consists of SEQ ID NO: 15. In some embodiments, the pharmaceutical
composition is used in for ng a tauopathy in a human subject in need thereof by
intravenously administering to the human subject any of the above-described pharmaceutical
compositions. In some embodiments, the anti-human tau antibody of the pharmaceutical
composition is administered to a human subject at a fixed dose of 150 mg once every four
weeks. In other embodiments, the uman tau dy of the pharmaceutical
composition is administered to a human subject at a fixed dose of 210 mg once every four
weeks. In yet other ments, the anti-human tau dy of the pharmaceutical
composition is administered to a human subject at a fixed dose of 700 mg once every four
weeks. In r embodiments, the anti-human tau antibody of the pharmaceutical
composition is administered to a human subject at a fixed dose of 2000 mg once every four
weeks. In other embodiments, the anti-human tau antibody of the pharmaceutical
composition is administered to a human subject at a fixed dose of 2100 mg once every four
weeks. In another embodiment, the anti-human tau antibody of the pharmaceutical
composition is administered to a human subject at a fixed dose of 4200 mg once every four
weeks. In certain instances, the ceutical composition is administered for at least 12
weeks (e.g., 12 weeks, 16 weeks, 20 weeks, 24 weeks, 30 weeks, 32 weeks, 36 weeks, 40
weeks, 48 weeks, 52 weeks). In certain instances, the tauopathy is progressive supranuclear
palsy, Alzheimer’s disease, amyotrophic lateral sclerosis/parkinsonism— dementia complex,
argyrophilic grain dementia, British type amyloid angiopathy, cerebral amyloid angiopathy,
corticobasal degeneration, Creutzfeldt- Jakob disease, dementia pugilistica, diffuse
neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD),
temporal ia with parkinsonism linked to some 17, frontotemporal lobar
degeneration, Gerstmann-Straussler-Scheinker disease, Hallervorden-Spatz e, inclusion
body myositis, multiple system atrophy, myotonic phy, Niemann-Pick e type C,
non-Guamanian motor neuron disease with brillary tangles, Pick's disease,
postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive
subcortical gliosis, globular glial tauopathy, subacute sclerosing panencephalitis, Tangle only
dementia, multi-infarct dementia, stroke, chronic traumatic encephalopathy, traumatic brain
injury, concussion, seizures, epilepsy, or acute lead encephalopathy. In one embodiment, the
tauopathy is progressive supranuclear palsy. In another embodiment, the tauopathy is
mer's disease.
Unless otherwise , all technical and scientific terms used herein have the same
g as commonly understood by one of ordinary skill in the art to which this invention
belongs. Although methods and materials similar or equivalent to those described herein can
be used in the ce or testing of the present ion, the exemplary methods and
materials are described below. All publications, patent applications, patents, and other
references ned herein are incorporated by nce in their entirety, In case of
t, the present application, ing definitions, will control. The materials, methods,
and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following
detailed description and from the claims.
Brief Description of Drawings
Fig. 1 provides the sequences of different forms of extracellular Tau (eTau), eTaul
(SEQ ID NO:7); eTau2 (SEQ ID NO:8), eTau3 (SEQ ID NO:9), and eTau4 (SEQ ID
NO:10), compared to the human Tau-441 isoforrn (2N4R) sequence (SEQ ID NO:6).
Fig. 2 is a schematic representation of the study design for the single ascending dose
study described in Example 1.
Fig. 3 is a graph depicting the exposure-response model (Bayesian Emax) of CSF
concentration versus eTau suppression.
Fig. 4 is a schematic representation of the study design for the multiple ascending
dose study described in Example 3.
Fig. 5 is a table providing the baseline demographic characteristics of the patients in
the multiple ascending dose study described in Example 3.
Fig. 6 is a table providing a summary of the e events for the le ascending
dose study described in Example 3.
Fig. 7 is a table providing a summary of the serum PK parameters for BIIB092 (at day
57 of the study).
Fig. 8 is a graphical depiction of the mean change in eTau concentrations over time.
There was a dose—dependent relationship between BIIB092 dose and the extent of eTau
suppression in the CSF.
is a table providing CSF free eTau as a percentage of baseline with BIIB092
dose.
Detailed Description
This disclosure features dosage regimens and formulations of anti-human tau
antibodies and tau-binding fragments thereof and their use in the treatment of thies
(e. g., disorders related to aggregates of tau such as progressive supranuclear palsy,
Alzheimer's disease, amyotrophic lateral sclerosis/parkinsonism— dementia complex,
argyrophilic grain dementia, British type d angiopathy, cerebral amyloid angiopathy,
corticobasal degeneration, feldt- Jakob disease, dementia pugilistica, e
neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD),
frontotemporal dementia with parkinsonism linked to chromosome 17, temporal lobar
degeneration, Gerstmann—Straussler—Scheinker disease, Hallervorden-Spatz disease, inclusion
body myositis, multiple system atrophy, myotonic dystrophy, n-Pick disease type C,
non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease,
postencephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive
subcortical gliosis, subacute sclerosing panencephalitis, Tangle only ia, multi-infarct
dementia, stroke, chronic traumatic encephalopathy, tic brain injury, concussion,
seizures, epilepsy, and acute lead encephalopathy).
Tau is a protein that plays a critical role in the pathogenesis of several disorders
tively ed to as tauopathies. There are several different isoforms of the
microtubule-associated protein, which are provided below:
Isoform Fetal-tau 0f352aa
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKAEEAGIGDTPSLE
DEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIP
AKTPPA?KTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVV
RTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKJQPGGGKVQIVYKPVDLSK
VTSKCGSLGN:HHKPGGGQVEVKSEKLDFKDRVQSK"GSLDN"THVPGGGNKK fiTH
KLT FREvAKAKTDHGAE IVYKS PWSGDTS PRHLSNVS sros :: DMVDS ADE
VSAS LAKQGL (SEQ ID NO:1)
m Tau-B of3816161
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSE
fiPGSfiTSDAKSTPTAfiAfiEAG GDTPSLfiDfiAAGHVTQARMVSKSKDGTGSDDKKAK
GADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSP
GSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPP{SPSSAKSRLQTAPVPMPDLKNVK
SKIGSTENLKHQPGGGKVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLD
FKDRVQSK"GSLDN"THVPGGGNKK fiTHKLTFQENAKAKTDHGAEIVYKSPVVSGD
SNVSSTGS :DMVDS PQLATLADEVSAS LAKQGL (SEQ ID N022)
Isoform Tau-C 0f410aa
WAEPRQRFfiVMfiDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLK?SPLQTPT?DGSE
EPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSL
EDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQAWATRI
APKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAV
VRTPP{SP8SA{SRLQTAPVPMPDLKNVKSK:GSTENLKHQPGGGKVQIVYKPVDLS
KVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIET
HKLTFRENAKA<TDHGAEIVY{SPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLAD
EVSASLAKQGL (SEQ ID NO:3)
Isoform Tau-D 0f383aa
MAEPRQSFfiVMfiDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKAEEAGIGDTPSLE
DEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIP
AKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVV
RTPPKS?SSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQI:WKKLDLSN
VQSKCGSKDN:KHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEK
LDFKDRVQSK—GSVDN'THVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVS
GDTSPRHLSNVSSTGS:DMVDSPQLATLADEVSASLAKQGL (SEQII)N(k4)
Isoform Tau-E 0f412aa
MAEPQQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSE
EPGSETSDAKSTPTAjAjEAGnGDTPSLEDEAAGHVTQARMVS{SKDGTGSDDKKAK
GADG{TKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSP
GSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVK
SKTGST?N7KHQPGGGKVQ—"NKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVD
LSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKI
TR?NAKAKTDHGAE:VYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATL
ADEVSASLAKQGL (SEQ ID N0:5)
Isoform Tau-F (2N4R) 0f441aa
WAFPRQRFfiVM{DHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKVSPLQTPT?DGSE
EPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSL
EDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGAAPPGQKGQAWATRI
PAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAV
VRTPPKSPSSA{SRLQTAPVPMPDLKNVKSKHGSTjWLKHQPGGGKVQ NK<LDLS
NVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSE
KLDFKDRVQSKZGSLDNITHVPGGGNKKIETHKLTERjNAKAKTDHGAfi VY<SPVV
SGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL(SEQIDPKI6)
Intracellular tau levels are increased in the brains of Alzheimer’s disease ts
when ed to non-demented controls (Barton, Am J. Pathol, 137 :497-502 (1990),
n, J. Neurochem, -753 (1992)). This increase in the levels of intracellular tau is
believed to be toxic to neurons since a reduction in the amount of intracellular tau has been
shown to be protective in mouse models of neurodegeneration (Rapoport et al., Proc. Natl.
Acad. Sci. USA, 99:6364-6369 , Robertson et al., Science, 316:750-754 (2007)), and
thus reducing the amount of intracellular tau can be therapeutically beneficial.
Secreted N-terminally truncated tau species, designated extracellular Tau (eTau), have
been identified. “eTau” as used herein, encompasses any Tau ptide that can be
detected in cerebrospinal fluid (CSF) or interstitial fluid (ISF). In some embodiments, eTau is
a polypeptide having a ce set forth in one of SEQ ID NOS.: 7-10 of Figure 1. The
eTau species varies from 171 amino acids for eTau1 to 67 amino acids for eTau4. Although
tau lacks a signal sequence, tau has been found released into culture medium from
neuroblastoma cells, tau-expressing non-neuronal cells, induced pluripotent stem cell-derived
human neurons, and mouse primary s. Thus, tau may be secreted entionally or
associated with exosomes or other ne vesicles. eTau has also been detected in the
brain ISF of both wild type and P301 S tau-expressing mice in microdialysis studies. It has
also been seen in the brain ISF of patients following tic brain injury. eTau has been
shown to regulate AB production and to increase neuronal hyperactivity (Bright et al.,
Neurobiology andAging, 36:693-709 (2015)). Treatment with an eTau-neutralizing antibody
reduces eTau-mediated neuronal hyperactivity. See, e.g.,
proposed that the eTau-driven neuronal hyperactivity increase leads not only to increased AB
secretion but also to a further increase in eTau secretion and thus, eTau and AB create a feed
forward disease mechanism that uates the disease. Thus, neutralizing eTau can inhibit
the spread of tau and tau pathology in the brain, reduce central nervous system AB levels and
the resulting al hyperactivity, and potentially slow the clinical progression into
dementia.
uman Tau Antibodies
One way of lizing tau is by using antibodies that bind tau. In certain
embodiments, these antibodies bind to an epitope within amino acids 1-25, 1-18, 9-18, 13-24,
-44, or 15-24 of SEQ ID NO:6. In a specific ment, an anti-tau antibody binds to an
epitope within GDRK (SEQ ID NO:11).
An exemplary anti—human tau antibody is designated “BIIBO92.” BIIBO92 is a
humanized IgG4/kappa antibody that recognizes human tau. The heavy chain variable
domain of the BIIBO92 antibody has the following amino acid sequence:
EVHLVESGGA LVKPGGSLRL SCAASGFSFS VRQA PGKGLEWVAE
ISSSGSRTYY
PDSVKGRFTI SRDNAKNTLY LQMNSLRAED TAMYYCSISW DGAMDYWGQG TTVTVSS
(SEQ ID NO: 12)
The light chain variable domain of the BIIBO92 antibody has the following amino acid
sequence:
DVVMTQSPLS LPVTLGQPAS ISCKSSQSIV HSNGNTY.?W YLQKPGQSPQ
LLVYKVSNRF
§GVPDRFSGS GSGTDFTLKI SRVEAEDVGT YYCFQGSLVP WAFGGGTKVE IK
(SEQ ID NO:13)
The heavy chain of the BIIBO92 dy has the following amino acid sequence:
EVHLVESGGA LVKPGGSLRL SCAASGFSFS KYGMSWVRQA PGKGLEWVAE
ISSSGSRTYY
PDSVKGRFTI SRDNAKNTLY LQMNSLRAED TAMYYCSISW WGQG
KGPSVFPLAP CSRS"SESTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY
SLSSVVTVPS SSLG"K"YTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPLLJ
PPKPKDTLMI SRTPEV"CVV VDVSQEDPEV DGVE VHNAKTKPRLLJ
EQFWSTYRVV
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP
SQEEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSRLTVD
KSRWQEGNVF
SCSVMHEALH NHYTQKSLSL SLGK (SEQ ID N0214)
The light chain of the BIIBO92 antibody has the following amino acid sequence:
DVVMTQSPLS LPVTLGQPAS ISCKSSQSIV HSNGNTY.?W QSPQ
LLVYKVSNRF
§GVPDRFSGS GSGTDFTLKI SRVEAEDVGT YYCFQGSJVP WAFGGGTKVILLJ
IKRTVAAPSV
FIFPPSDEQL KSGTASWCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE
QDSKDSTYSL
SSTLTLSKAD YACE VTHQGLSSPV TKSFNRGEC (SEQ ID NO:15)
In some embodiments, the anti-human tau antibody or tau-binding fragment thereof
ses the three light chain le domain CDRs of BIIB092. In some embodiments,
the anti-human tau antibody or tau-binding fragment f comprises the three heavy chain
le domain CDRs of BIIB092. In still other embodiments, the anti-human tau antibody
or tau-binding fragment thereof comprises the three heavy chain variable domain CDRs and
the three light chain variable domain CDRs of BIIB092. The CDRs can be based on any CDR
definition in the art, e. g., the definitions of Kabat, Chothia, Chothia from Abysis, enhanced
Chothia/AbM, or based on the contact definition. CDR sequences of BIIB092 are provided in
Table 1 below.
Table 1: Sequences of the CDRs of BIIB092
VH CDRl KYGMS (SEQ ID NO:16)
VH CDR2 TISSSGSRTYYPDSVKG (SEQ ID NO:17)
In some embodiments, the uman tau antibody or tau-binding fragment thereof
comprises a VH CDR1 comprising or consisting of the amino acid sequence set forth in SEQ
ID NO: 16, a VH CDR2 sing or consisting of the amino acid sequence set forth in SEQ
ID NO: 17 ; and a VH CDR3 comprising or consisting of the amino acid sequence set forth in
SEQ ID NO:18, a VL CDR1 comprising or consisting of the amino acid sequence set forth in
SEQ ID NO: 19, a VL CDR2 comprising or consisting of the amino acid sequence set forth in
SEQ ID NO:20; and a VL CDR3 comprising or ting of the amino acid sequence set
forth in SEQ ID NO:21.
In some embodiments, the anti-human tau antibody or tau-binding fragment thereof
comprises a VH comprising or consisting of the amino acid ce set forth in SEQ ID
NO: 12. In some embodiments, the anti-human tau antibody or tau—binding fragment thereof
comprises a VL comprising or consisting of the amino acid sequence set forth in SEQ ID
NO: 13. In some embodiments, the anti-human tau antibody or tau—binding fragment f
comprises a VH comprising or consisting of the amino acid sequence set forth in SEQ ID
NO: 12 and a VL comprising or consisting of the amino acid sequence set forth in SEQ ID
NO:13.
In some embodiments, the anti-human tau antibody or nding fragment thereof
comprises a heavy chain comprising or consisting of the amino acid ce set forth in
SEQ ID NO: 14. In some embodiments, the anti-human tau antibody or tau-binding fragment
thereof comprises a light chain comprising or consisting of the amino acid sequence set forth
in SEQ ID NO: 15. In some embodiments, the anti-human tau dy or tau-binding
fragment thereof comprises a heavy chain comprising or consisting of the amino acid
sequence set forth in SEQ ID NO:14 and a light chain comprising or consisting of the amino
acid sequence set forth in SEQ ID NO:15.
In certain embodiments, the anti-human tau antibody is an IgG antibody. In specific
embodiments, the anti-human tau antibody has heavy chain constant region chosen from, e.g.,
IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE. In one embodiment, the anti-
human tau antibody is of the IgG4 isotype. In another embodiment, the anti-human tau
dy is of the IgGl isotype. In yet another embodiment, the anti-human tau antibody is
of the IgGZ isotype. In another embodiment, the anti—human tau antibody is of the IgG3
isotype. In further embodiments, the anti-human tau antibody has a light chain nt
region chosen from, e. g., a human kappa light chain constant region or a human lambda light
chain nt region. In a certain embodiment, the anti-human tau antibody is an
IgG4/human kappa light chain antibody.
In some embodiments, the anti-human tau antibody is a full-length (whole) antibody
or substantially full-length. The protein can include at least one, and preferably two, complete
heavy chains, and at least one, and preferably two, complete light chains. In some
ments, the anti-human tau antibody is a tau-binding fragment. In some ces, the
tau-binding antibody fragment is a Fab, a Fab’, an F(ab')2, a Facb, an Fv, a single chain Fv
(scFv), a sc(Fv)2, or a diabody.
The heavy chain and light chain of the anti-human tau antibodies disclosed herein
may also include signal sequences. The signal sequences can be selected from those known
in the art, for example, MDMRVPAQLLGLLLLWFPGSRC (SEQ ID NO:22) or
MDMRVPAQLLGLLLLWLPGARC (SEQ ID NO:23).
Antibodies, such as BIIB092, or nding fragments thereof can be made, for
example, by preparing and sing synthetic genes that encode the recited amino acid
sequences or by mutating human ne genes to provide a gene that encodes the d
amino acid sequences. Moreover, this antibody and other anti-human tau antibodies can be
ed, e.g., using one or more of the following methods.
Methods of ing Anti—Human tau Antibodies
Anti-human tau antibodies or tau-binding fragments may be produced in bacterial or
eukaryotic cells. Some dies, e.g., Fab’s, can be produced in bacterial cells, e.g, E. coli
cells. Antibodies can also be produced in eukaryotic cells such as transformed cell lines (e. g.,
CHO, 293E, COS). In addition, dies (e.g., scFv’s) can be expressed in a yeast cell such
as Pichia (see, e.g., Powers et al., JlmmunolMethods. 251:123-35 (2001)), Hanseula, or
Saccharomyces. To produce the antibody of interest, a polynucleotide or polynucleotides
encoding the antibody is/are constructed, introduced into an expression vector or expression
vectors, and then expressed in suitable host cells. To improve expression, the nucleotide
ces of the light and heavy chain genes can be recoded without ng (or minimally
ng — e.g., removal of a C-terminal residue of the heavy or light chain) the amino acid
sequence. The areas for potential recoding include those associated with translation initiation,
codon usage, and possible unintended mRNA splicing. Polynucleotides encoding an anti-
human tau antibody comprising the VH and/or VL, HC and/or LC of the tau antibodies
described herein would be readily oned by the ordinarily skilled artisan.
Standard molecular biology techniques are used to e the inant
expression vector(s), transfect the host cells, select for transformants, culture the host cells,
and recover the anti-human tau antibody.
If the anti-human tau antibodies or nding fragments are to be expressed in
bacterial cells (e.g, E. coli), the expression vector should have characteristics that permit
amplification of the vector in the bacterial cells. onally, when E. coli such as JM109,
DHSu, HB101, or XLl-Blue is used as a host, the vector must have a promoter, for example,
a lacZ promoter (Ward et al., 4-546 (1989), araB er (Better et al., Science,
240: 1041-1043 (1988)), or T7 promoter that can allow efficient expression in E. coli.
Examples of such vectors include, for example, M13—series vectors, pUC-series vectors,
pBR322, pBluescript, pCR-Script, pGEX-SX-l (Pharmacia), “QIAexpress system”
(QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably
BL21 expressing T7 RNA polymerase). The sion vector may contain a signal
sequence for antibody secretion. For production into the periplasm of E. wit, the peZB signal
sequence (Lei et al., J. Bacteriol, 169:4379 (1987)) may be used as the signal sequence for
antibody secretion. For bacterial expression, calcium chloride methods or electroporation
methods may be used to uce the expression vector into the bacterial cell.
If the antibody is to be expressed in animal cells such as CHO, COS, and NIH3T3
cells, the expression vector includes a promoter necessary for expression in these cells, for
example, an SV40 promoter (Mulligan er al, , 277: 108 (1979)) (e.g., early simian
virus 40 promoter), MMLV-LTR promoter, EFlOt promoter (Mizushima 62‘ al. Nucleic Acids
Res., 18:5322 ), or CMV er (e. g., human cytomegalovirus ate early
er). In addition to the nucleic acid sequence encoding the immunoglobulin or domain
thereof, the recombinant sion vectors may carry additional ces, such as
sequences that regulate replication of the vector in host cells (e.g., origins of replication) and
selectable marker genes. The selectable marker gene facilitates selection of host cells into
which the vector has been introduced (see e. g., US. Pat. Nos. 4,399,216, 665 and
,179,017). For example, typically the selectable marker gene confers resistance to drugs,
such as G418, hygromycin, or methotrexate, on a host cell into which the vector has been
introduced. Examples of vectors with selectable markers e pMAM, pDR2, pBK-RSV,
pBK-CMV, pOPRSV, and pOP13.
In one ment, the anti-human tau antibodies are produced in mammalian cells.
Exemplary mammalian host cells for expressing an antibody include Chinese Hamster Ovary
(CHO cells) (including dlzfr’ CHO cells, described in Urlaub and Chasin (1980) Proc. Natl.
Acacl. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e. g., as described in
Kaufman and Sharp (1982) M01. Biol. 159:601-621), human embryonic kidney 293 cells
(e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphocytic cell lines, e.g., NSO myeloma
cells and SP2 cells, and a cell from a transgenic animal, e.g., a transgenic mammal. For
example, the cell is a mammary epithelial cell. In a specific embodiment, the mammalian
cell is a CHO-DG44I cell.
In an exemplary system for antibody expression, a recombinant expression vector
encoding both the uman tau antibody heavy chain and the anti—human tau dy light
chain of an anti-human tau antibody (6. g, BIIB092) is introduced into dlzfr’ CHO cells by
calcium phosphate—mediated transfection. Within the recombinant expression vector, the
antibody heavy and light chain genes are each operatively linked to enhancer/promoter
regulatory elements (e. g., derived from SV40, CMV, adenovirus and the like, such as a CMV
enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter
regulatory element) to drive high levels of transcription of the genes. The recombinant
expression vector also carries aDHFR gene, which allows for selection of CHO cells that
have been transfected with the vector using methotrexate selection/amplification. The
ed transformant host cells are cultured to allow for expression of the antibody heavy
and light chains and the antibody is recovered from the culture medium.
Antibodies can also be produced by a transgenic animal. For example, US. Pat. No.
,849,992 describes a method of expressing an antibody in the mammary gland of a
transgenic mammal. A transgene is constructed that includes a milk-specific promoter and
nucleic acids encoding the dy of interest and a signal sequence for secretion. The milk
produced by females of such transgenic mammals includes, secreted-therein, the dy of
interest. The antibody can be purified from the milk, or for some applications, used directly.
Animals are also provided comprising one or more of the nucleic acids described herein.
The antibodies of the present disclosure can be isolated from inside or outside (such
as medium) of the host cell and d as substantially pure and nous antibodies.
Methods for isolation and ation commonly used for antibody purification may be used
for the isolation and purification of antibodies, and are not limited to any particular method.
Antibodies may be isolated and purified by appropriately selecting and combining, for
example, column chromatography, filtration, ultrafiltration, salting out, t precipitation,
solvent tion, distillation, immunoprecipitation, lyacrylamide gel
electrophoresis, isoelectric focusing, is, and recrystallization. Chromatography
es, for example, affinity chromatography, ion exchange tography, hydrophobic
chromatography, gel filtration, e-phase tography, and adsorption
chromatography (Strategies for Protein Purification and Characterization: A Laboratory
Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996).
Chromatography can be carried out using liquid phase chromatography such as HPLC and
FPLC. Columns used for affinity chromatography include protein A column and protein G
column. Examples of columns using protein A column include Hyper D, POROS, and
Sepharose FF (GE Healthcare Biosciences). The present disclosure also includes antibodies
that are highly purified using these purification methods.
Anti-Human Tau Antibody Formulations
Any of the anti-human tau dies described herein can be formulated as a
pharmaceutical composition. The pharmaceutical ition can comprise 10 mg/mL, 60
mg/mL or 50 mg/mL of an anti—human tau antibody described herein. In a particular
embodiment, the pharmaceutical ition comprises 50 mg/mL of an anti-human tau
antibody described herein. In addition, the pharmaceutical composition includes histidine at
a concentration of 20 mM, sucrose at a concentration of 250 mM, and polysorbate—80 at a
concentration of 0.05% (w/v). In certain cases, the pharmaceutical composition further
includes 50 uM diethylenetriamine pentaacetic acid (DTPA). The pharmaceutical
composition has a pH of 6.0.
In some instances, the anti-human tau antibody of the pharmaceutical composition
comprises an immunoglobulin heavy chain le region (VH) comprising VH
complementarity determining regions WH-CDRs) and an immunoglobulin light chain
variable region (VL) comprising VL-CDRs. The VH-CDRl comprises or consists of the
amino acid sequence of SEQ ID NO: 16; VH-CDR2 comprises or consists of the amino acid
sequence of SEQ ID NO: 17; and VH-CDR3 comprises or consists of the amino acid
ce of SEQ ID NO: 18. The VL-CDRI comprises or consists of the amino acid
sequence of SEQ ID NO: 19; VL-CDR2 comprises or consists of the amino acid sequence of
SEQ ID N020; and 3 comprises or consists of the amino acid sequence of SEQ ID
NO:21.
In certain cases; the anti-human tau antibody of the pharmaceutical composition
comprises a VH comprising or consisting of SEQ ID NO: 12. In certain cases, the uman
tau antibody of the pharmaceutical composition comprises a VL comprising or consisting of
SEQ ID NO: 13. In certain cases, the anti-human tau antibody of the pharmaceutical
composition comprises a VH comprising or consisting of SEQ ID N012 and a VL
comprising or consisting of SEQ ID NO:13.
In certain cases; the anti-human tau antibody of the pharmaceutical composition
comprises a heavy chain comprising or consisting of SEQ ID NO:14. In certain cases; the
anti-human tau antibody of the pharmaceutical composition comprises a light chain
comprising or consisting of SEQ ID NO: 15. In certain cases; the uman tau antibody of
the pharmaceutical composition comprises a heavy chain sing or consisting of SEQ ID
NO:14 and a light chain comprising or consisting of SEQ ID NO:15.
Indications
The anti-human tau dies described herein are expected to be useful in the
treatment of tauopathies. Tauopathies are a class of neurodegenerative diseases associated
with the pathological aggregation of tau n in neurofrbrillary or gliofrbrillary tangles in
the human brain.
Exemplary tauopathies e progressive supranuclear palsy; Alzheimer's e;
amyotrophic lateral sclerosis/parkinsonism— dementia complex; argyrophilic grain ia;
British type amyloid angiopathy; cerebral amyloid angiopathy; corticobasal ration;
feldt- Jakob disease; dementia pugilistica; e neurofrbrillary tangles with
calcification, Down's syndrome, frontotemporal dementia (FTD), frontotemporal ia
with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, Gerstmann-
Straussler-Scheinker e, Hallervorden-Spatz e, inclusion body myositis, multiple
system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian motor
neuron disease with neurofibrillary tangles, Pick’s disease, postencephalitic parkinsonism,
prion protein al amyloid angiopathy, ssive subcortical gliosis, globular glial
tauopathy, subacute sclerosing panencephalitis, Tangle only dementia, multi-infarct
ia, stroke, chronic traumatic encephalopathy, traumatic brain , concussion,
seizures, epilepsy, and acute lead encephalopathy.
In one embodiment, the anti—human tau antibodies described herein are used to treat
progressive supranuclear palsy.
In another embodiment, the anti-human tau antibodies described herein are used to
treat Alzheimer's disease.
Methods of Treatment
The disclosure features methods of treating human subjects with a tauopathy (see
above) with an anti-human tau antibody disclosed herein or a pharmaceutical composition
sed herein. In one embodiment, the tauopathy is ssive supranuclear palsy. In
another ment, the tauopathy is Alzheimer’s disease.
In certain embodiments, the method comprises stering to the human subject in
need thereof an anti-human tau antibody in an amount effective to reduce significantly the
level of tau (e. g., total Tau and/or free Tau) in an ellular fluid (e. g., cerebrospinal fluid
(CSF), interstitial fluid (ISF), blood, or a blood fraction (e.g., serum or plasma)) in the
individual. “Free Tau” refers to a tau polypeptide that is not bound to an anti-human tau
antibody. In one embodiment, the free Tau is extracellular Tau (eTau). “Total Tau” includes
free Tau and Tau that is bound to an anti-human tau dy. In one particular embodiment,
the method comprises administering to the human subject in need thereof an anti-human tau
antibody in an amount effective to reduce significantly the level of free eTau. In some
embodiments, the level of tau (e.g, total Tau and/or free Tau) is significantly reduced within
36 hours of administration of the anti-human tau antibody. In some embodiments, the level of
tau (e.g., total Tau and/or free Tau) is significantly reduced within 24 hours of administration
of the anti—human tau antibody. In some embodiments, the level of free eTau is significantly
reduced within 24 hours of administration of the anti-human tau antibody. In some cases, an
ive amount of an anti—human tau antibody is an amount that is effective to reduce
significantly the level of tau (e. g, total Tau and/or free Tau) in an extracellular fluid within
48 hours, 36 hours, within 24 hours, within 12 hours, within 8 hours, within 4 hours, within 2
hours, within 1 hour, within 30 minutes, within 15 minutes, or within 5 s, of
administration of the anti-human tau antibody. For example, in some cases, an effective
amount of an anti-human tau antibody is an amount that is effective to reduce significantly
the level of Tau (e.g., total Tau and/or free Tau) in an extracellular fluid within from 5
minutes to about 10 minutes, from about 10 minutes to about 15 minutes, from about 15
minutes to about 30 minutes, from about 30 minutes to about 1 hour, from about 1 hour to
about 2 hours, from about 2 hours to about 4 hours, from about 4 hours to about 8 hours, from
about 8 hours to about 12 hours, from about 12 hours to about 24 hours, from about 24 hours
to about 36 hours, from about 24 to about 48 hours, or from about 36 hours to about 48 hours.
A significant ion in the level of tau (e.g., total Tau and/or free Tau) in an
extracellular fluid (e. g., CSF, ISF, blood, or a blood fraction (e. g., serum or plasma)) of an
individual is an at least 30% reduction, at least 35% reduction, at least 40% reduction, at least
45% reduction, at least 50% reduction, an at least 55% reduction, an at least 60% reduction,
an at least 65% ion, an at least 70% reduction, an at least 75% reduction, an at least
80% reduction, an at least 85% reduction, an at least 90% reduction, an at least 95%
reduction, or a greater than 90% reduction. In some instances, the cant ion is a
statistically significant reduction. In some instances, the significant reduction is a clinically
significant reduction. In some embodiments, the level of tau (e. g, total Tau and/or free Tau)
in an extracellular fluid is d to a normal, control level (e.g, about 100 . In some
embodiments, the level of Tau (e. g., total Tau and/or free Tau) in an extracellular fluid is
reduced to an undetectable level. In some cases, the extracellular fluid is CSF. In other cases,
the extracellular fluid is ISF. In other cases, the extracellular fluid is plasma. In other cases,
the ellular fluid is whole blood. In other cases, the extracellular fluid is serum.
In certain instances, an anti-human tau antibody described herein is administered to
the human subject at a fixed dose of 2000 mg. In certain instances, an anti-human tau
antibody is administered to the human subject at a fixed dose of 2100 mg. In other instances,
an anti—human tau antibody is administered to the human subject at a fixed dose of 150 mg. In
further ces, an uman tau antibody is administered to the human subject at a fixed
dose of 4200 mg. In certain embodiments, the above-noted fixed doses of an anti-human tau
antibody described herein are stered to the human subject once every four weeks.
In certain cases, an anti-human tau antibody described herein is administered to the
human subject as part of a pharmaceutical composition. In one embodiment, the
pharmaceutical composition comprises 50 mg/mL of the anti—human tau antibody, 20 mM
histidine, 250 mM sucrose, and 50 uM DTPA. The pharmaceutical composition has a pH of
6.0. In certain ments, the ceutical composition is administered to the human
subject in an amount sufficient to deliver a fixed dose of 2000 mg of the anti-human tau
antibody. In certain embodiments, the pharmaceutical composition is administered to the
human subject in an amount sufficient to r a fixed dose of 2100 mg of the uman
tau antibody. In certain embodiments, the pharmaceutical composition is administered to the
human subject in an amount sufficient to deliver a fixed dose of 700 mg of the anti-human
tau antibody. In certain embodiments, the ceutical ition is administered to the
human subject in an amount sufficient to deliver a fixed dose of 150 mg of the anti-human
tau antibody. In certain embodiments, the pharmaceutical composition is administered to the
human subject in an amount sufficient to deliver a fixed dose of 210 mg of the anti-human
tau antibody. In certain embodiments, the pharmaceutical composition is administered to the
human t in an amount sufficient to deliver a fixed dose of 4200 mg of the anti-human
tau antibody.
In certain embodiments of these methods, the anti-human tau antibody is administered
to the human subject in need thereof by an intravenous route.
In n embodiments, the anti-human tau antibody comprises an globulin
heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL),
wherein the VH comprises VH complementarity determining regions (VH-CDRs), wherein
VH-CDRI comprises or consists of the amino acid sequence of SEQ ID NO:16; VH-CDR2
comprises or consists of the amino acid sequence of SEQ ID N017; and VH-CDR3
comprises or consists of the amino acid sequence of SEQ ID N018; and the VL comprises
VL-CDRs, wherein 1 comprises or consists of the amino acid sequence of SEQ ID
N0119; VL—CDR2 comprises or consists of the amino acid sequence of SEQ ID NO:20, and
3 comprises or consists of the amino acid sequence of SEQ ID NO:21.
In certain embodiments, the VH of the uman tau antibody comprises or consists
of SEQ ID NO: 12 and the VL comprises or consists of SEQ ID NO:13.
In certain ments, the anti—human tau antibody comprises a heavy chain and a
light chain, wherein the heavy chain comprises or consists of SEQ ID NO: 14 and the light
chain comprises or consists of SEQ ID NO: 15.
The following example is not to be construed as limiting the scope of the invention in
any way.
Examples
Example 1: A Single Ascending Dose Study of an Anti-Human Tau Antibody, BIIBO92
BIIBO92 is a zed antibody that recognizes human ellular Tau (eTau).
The purposes of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK)
of BIIBO92 as well as the codynamic (PD) effects of BIIBO92 on extracellular tau
(eTau) after a single intravenous (IV) infusion of BIIBO92 in y human subjects.
Specifically, BIIBO92 was tested to determine its efficacy in preventing transmission of tau
pathology by g and reducing free eTau in human CSF.
This study was a randomized, double blind, placebo controlled single ascending dose
trial. Healthy subjects (age: 21-65) in 6 ascending dose cohorts (21mg, 70mg, 210mg,
700mg, 2100mg and 4200mg of BIIBO92) comprised of 8 subjects per cohort were
stered a single intravenous (IV) infusion of BIIBO92 (6 subjects) or placebo (2
subjects). See, Safety assessments, and serum and CSF samples (including 4 lumbar
punctures) were collected over 12 weeks. cokinetic parameters (in serum and CSF)
and pharmacodynamic measures (CSF concentrations of free eTau) and corresponding
change and t change from baseline were evaluated.
Increases in peak (Cmax) and exposure (AUC[INF]) of BIIBO92 in serum appeared to
be dose proportional. The terminal elimination half-life of BIIBO92 was approximately 25
days. CSF concentrations of BIIBO92 increased with dose and appeared dose-proportional.
CSF-to-serum ratio of BIIBO92 was approximately 0.2% and similar across the dose range.
Most adverse events were mild. There were no serious adverse events or discontinuations due
to adverse events. The extent and duration of suppression of eTau increased with dose.
Following single doses of BIIBO92, suppression of CSF eTau at 28 days ranged from 65% to
96% at doses ranging from 70mg to 4200mg.
The ability of BIIBO92 to robustly suppress CSF concentrations of free eTau in this
phase 1 study suggests that 2 has utility for the treatment of human tauopathies (e.g.,
progressive supranuclear palsy). Single doses of BIIBO92 stration were safe and well
tolerated at doses up to 4200mg.
Example 2: an Emax Model
An exposure-response model (Bayesian Emax) of CSF concentration versus eTau
suppression was constructed (see, . The Bayesian Emax model captured the observed
eTau suppression reasonably well.
Example 3: Multiple ing Dose Study of an Anti-Human Tau dy: BIIB092: in
Patients with Progressive Supranuclear Palsy
The purpose of this study was to assess the , tolerability, pharmacokinetic (PK)
and pharmacodynamic (PD) effects of BIIB092 on free extracellular tau (eTau) after
intravenous (IV) infusions of BIIB092 every 4 weeks (Q4W) in patients with progressive
supranuclear palsy (PSP). Specifically, this study was designed to evaluate the safety profile
of BIIB092 and its ability to reduce free eTau in the CSF of patients with PSP.
The baseline demographic characteristics for this study are shown in This
study was a randomized, double-blind, placebo-controlled, multiple ascending dose trial of 48
patients with PSP, of whom 12 (25%) received placebo. Three ascending dose panels (150
mg, 700 mg, and 2100 mg) comprised of 8 patients per panel, were administered IV infusions
of BIIB092 (6 patients) or placebo (2 patients) Q4W for 12 weeks, an additional 24 patients
were treated with BIIB092 at a dose of 2100 mg (18 patients) or placebo (6 patients)
administered Q4W for 12 weeks. See, All patients were also offered the unity
to participate in an open-label extension study. Safety assessments and serum and CSF
samples were collected over the 12 weeks. PK parameters (in serum and CSF), PD measures
(concentrations of CSF free eTau), and corresponding change and t change from
baseline were evaluated, Clinical outcome measures including the PSP Rating Scale and
Schwab and England Activities of Daily Living Scale were also employed.
Patients’ mean age was 67.4 i 5.5 years, 54.2% were female. Concentrations of
BIIB092 in serum and CSF increased with dose. The percentages of patients experiencing
adverse events (AEs) were similar in the BIIB092 and placebo groups (~75%). Most AEs
were mild. See, There were no deaths or tinuations due to AEs. A summary of
the serum PK ters for BIIB092 is provided in FIG. ’7. Mean suppression of CSF free
eTau was approximately 90—96% (Day 29) and 91—97% (Day 85) at doses g from 150
mg to 2100 mg. Although CSF and serum exposures and reductions of CSF free eTau
sed with 2 dosage, significant reductions of CSF free eTau were observed with
all dosages employed in the study. See, FIGS. 8 and 9.
Administration of multiple doses of BIIB092 was safe and well tolerated at doses up
to 2100 mg in patients with PSP.
e 4: BIIB092 Dose Selection Based on Simulated PK and eTau Suppression
Using the estimated PK-PD model parameters and the variability around these
parameters in PSP patients, 1000 profiles were simulated and the time course of PK in serum
and CSF and PD (eTau) in CSF were obtained for two doses, namely 2000 mg and 700 mg of
BIIB092 stered once every 4 weeks (Q4W). eTau concentrations were converted to
percent suppression, relative to each subj ect’s baseline value, prior to summarization based
on the tions. Table 1 below shows summary statistics of percent suppression of eTau
relative to baseline levels at 4 weeks, 12 weeks, 24 weeks, and 48 weeks following the 2000
mg Q4W dosing n.
Table 1: Summary Statistics of Percent Suppression of eTau Relative to Baseline Following
2000 mg Q4W (Simulated)
tic 4 Weeks 12 Weeks 24 Weeks 48 Weeks
N 1000 1000 1000 1000
Median 96.46 97.46 97.57 97.58
Minimum 93.87 94.80 94.82 94.82
Maximum 98.25 98.92 99.03 99.04
10th percentile 95.35 96.34 96.43 96.43
90th percentile 97.37 98.25 98.39 98.40
Table 2 shows summary statistics of percent suppression of eTau relative to baseline
levels at 4 weeks, 12 weeks, 24 weeks, and 48 weeks ing the 700 mg Q4W dosing
regimen.
Table 2: Summary Statistics of Percent Suppression of eTau Relative to Baseline
Following 700 mg Q4W (Simulated)
Statistic 4 Weeks 12 Weeks 24 Weeks 48 Weeks
N 1000 1000 1000 1000
Median 93128 94.75 94194 9495
Minimum 88175 89.97 90.04 90.04
Maximum 9631 97.68 97196 98100
10th percentile 9185 93.15 9327 93 .28
90th percentile 94158 96.02 9628 96.30
Both 2000 mg and 700 mg doses of BIIBO92, stered Q4W lead to robust
suppression of eTau at trough. The 2000 mg dose of BIIBO92 is associated with slightly
higher ssion (3 to 5%) at trough than the 700 mg dose. Ninety percent of all subjects
that are dosed with the 2000 mg Q4W dose are ed to have a percentage suppression of
eTau at or above 96% at trough. Ninety percent of all subjects that are dosed the 700 mg
Q4W dose are expected have a percentage suppression of eTau at or above 93% at trough.
Given the robust and persistent suppression of eTau up to 12 weeks postdose at doses
at and above 210 mg that were studied, and the ~2x higher CSF concentrations of BIIBO92
observed in PSP patients compared to healthy subjects, dosing 2 can also be done on a
less frequent basis, e.g., once every 12 weeks (Q12W). Simulations were performed using the
same PK-PD model for a 2000 mg dose, stered Q12W. eTau suppression is
summarized in Table 3.
Table 3: Summary Statistics of Percent Suppression of eTau Relative to Baseline Following
2000 mg Q12W (Simulated)
Statistic 4 Weeks 12 Weeks 24 Weeks 28 Weeks 48 Weeks
(trough)
h) (trough)
N 1000 1000 1000 1000 1000
Median 96.47 90.08 9035 96.64 90.36
Minimum 93.46 74.05 74. 13 93.54 74.13
Maximum 98.22 9554 9605 98.37 96.15
10th percentile 95.35 86.01 86.20 95.46 86.21
90th percentile 97,37 92,79 93 i 11 9754 93.15
Ninety percent of all subjects that are administered the 2000 mg Q12W dose are expected
have a
percentage ssion of eTau at or above 86% at trough (i.e., end of the 12-week dosing
interval). However, subjects are expected to be at or above 95% suppression during the one
month immediate to the infusion, with slightly attenuated suppression in the ensuing 2
months.
Overall, Q12W dosing is also expected to be associated with robust and persistent lowering
eTau and may be preferred by patients and caregivers.
Example 5: BIIB092 Formulation Optimization for Excipient Content
In this excipient optimization stability, BIIB092 was evaluated at 10 mg/mL in 20
histidine buffer at pH 5.5, 6.0, and 6.5, containing 0.05% PS-80 and 50 uM DTPA, plus
either 250 mM sucrose or 250 mM sorbitol. In addition, BIIB092 was evaluated at 20 mg/mL
and 50 mg/mL in 20 mM histidine at pH 6.0 containing 0.05% PS-80, 50 uM DTPA, and
250 mM sucrose. A list of the formulations is shown in Table 4.
Table 4. Summary of ations for BIIB092 ent Optimization Study
E1 20mM 5.5 250 n. 50 10
E2 20 mM 6.0 250 0.05 50 10
E3 20mM 6.5 250 1-“—
E4 20mM 5.5 0
E5 20mM 6.0 0 250 50
E6 20 mM 6.5 0 250 0.05 50 10
E7 20mM 6.0 250 1-“—
Es 20mM 6.0 250 1-“—
All formulations were stored at /75i5%RH for up to three months and at 5i3°C and
2°C/60 5%RH up to 12 months. Initial and time point samples were ted for API
stability by appearance, pH, A230, HIAC, SEC, CEX, and potency ELISA. Peptide mapping
analysis was performed only at the initial, two month, and 12-month time points. ow
imaging was evaluated only at the three-month time point. The test methods are shown in
Table
and summary of testing at each time point is shown in Table 6.
Table 5. Analytical Testing for 2 Excipient Optimization Study
Appearance physical state, color, clarity
%acidic variants, %main peak, %basic variants
%monomer %HMW %LMW
cumulative counts per mL at Z 2 um, Z 5 mm, 2 10 mm,
2 25 um
Particulates (Z 2 mm, 2 5 um, 2 5 mm with AR 2 0.85,
210 um, 2 25 um)
Potency ELISA %Relative Potency 3
Peptide Mapping IPNOO? chemical degradation 3
1 Testing
was performed on 3 X 0.5 mL runs, included data from all three runs
2 MFI was only tested and reported at the three-month time point
3 ELISA and e mapping testing were performed only at the initial, two month, and final
time points
Table 6. Pull Schedule for BIIB092 Excipient Optimization Study
25i2°C/60i5%RH
40i2°C/75d:5%RH B A C
A = Testing according to Table 2, excluding MFI.
B = Testing according to Table 2, excluding ELISA, MFI and
peptide map.
C = Testing ing to Table 2, ing ELISA and peptide
D = Testing of formulations El-E3, E7, and E8 according to Table 2, except MFI, ELISA
and peptide map.
E = Testing of formulations E1-E3, E7, and E8 according to Table 2, except MFI.
Appearance
All samples at all time points and conditions except for one were ed to be clear,
colorless ons, free of any visible t-related particulates. One sample (E3, six
month, 25i2°C/60°5% RH) was noted to contain a single large white particle, which was
considered to be a contaminant and prevented further testing of that particular sample.
Measurement ofpH
All samples at all time points and ions exhibited pH values that were within
:01 pH units of the nominal values for each formulation. Any observed differences in pH
were therefore within the ility of the method.
Protein Content by Ultraviolet/Visible Spectroscopy
All samples at all time points and conditions exhibited n concentrations that did
differ significantly from their respective l values. Formulations targeted to 10 mg/mL
(E1 — E6) all exhibited protein concentrations between 9.8 — 11.4 mg/mL. Note that the
measured concentrations of the ol formulations (E4 — E6) were approximately 0.5
mg/mL higher than those of the sucrose formulations (E1 — E3), but this merely reflects
slightly higher concentrations from sample preparation. Formulation E7 (targeted to 20
mg/mL) ranged from 19.0 — 20.2 mg/mL, and E8 (targeted to 50 mg/mL) ranged from 50.0 —
53.7 mg/mL. Protein content by A280 demonstrated no significant trends in protein
concentration hout the stability time points for any of the formulations .
Particle Count (HIAC)
In all ations, increases in the number of larger particles (10 um and 25 nm)
were observed across the stability time points. However, there was no dependence of particle
formation on e temperature. Formulations E1 — E3 exhibited overall increases in large
particle counts out to the 12-month time point, any differences between the three
formulations are likely due to the variability of the method. While the trends were not
ely strong, relative to the noise, it should be noted that the absolute magnitude of
counts was considerable in the samples. Particle increases were especially pronounced in the
E7 and E8 formulations (with 20 mg/mL and 50 mg/mL of API, respectively); particles at 10
um in E7 increased from 12 counts at the initial time point to 1161 counts for the nine month
/ 25°C/60% RH sample, particles at 10 nm in E8 increased from 18 counts at the initial time
point to 1003 counts for the nine month / 25°C/60% RH sample. Particle counts in these two
samples at other longer range stability time points and conditions were also much higher than
the l particle counts. Differences between storage temperatures are likely due to
variability of the method. For the formulations E4 - E6, which were only tested out to three
months, particle counts out to that time point were comparable to those observed in E1 — E3,
and smaller than those ed in E7 — E8.
Size ion Chromatography
At each time point, small but significant decreases in percent HMW were observed
for all formulations as stability condition temperature increased. Generally, the temperature-
dependent differences in HMW impurities were smaller for formulations (E1 — E3) prepared
with 250 mM sucrose than for formulations (E4 — E6) ed with 250 mM sorbitol. At the
12-month time
point, formulations E2 and E3 exhibited the highest main peak , indicating the least
aggregation and fragmentation of the API in these formulations.
Within the time point data for each formulation, there is no solid evidence for
sing HMW t at any storage condition. The difficulty in ing time points
makes a more distinct conclusion difficult. r, some comparison can be made between
time points, when the reference standard performance in each sample queue is comparable.
Two such time points were the initial and final (12 month) time points, for which all
reference standard injections exhibited 15:0. 1% HMW. At these two time points, there was
little difference in HMW content for the study samples.
For each time point, the percent LMW did not appear to change significantly
(increases of between 0.1 — 0.3% for some formulations and time points / conditions, others
saw no
change in percent LMW).
Cation Exchange tography
t acidic variants increased over time for all formulations, and demonstrated
greater increases with increasing temperature, and appeared to be lower with lower pH,
Conversely, percent basic variants, while increasing over time and with higher stability
temperature, demonstrated lower variants with increasing pH. There did not appear to be any
significant differences in either percent acidic or percent basic variants in samples formulated
at higher concentrations (E7 — 20 mg/mL, E8 — 50 mg/mL) versus comparable sample at 10
mg/mL at the same pH (6.0).
Overall, the percent main peak for the samples that were tested out to twelve months
(E1 — E3, E7 — E8) appeared to be able for those samples at all concentrations that
were formulated at pH 5.5 and 6.0. The sample formulated at pH 6.5 (E3) exhibited
somewhat lower percent main peak versus those samples at lower pH (70.6% for E3 versus
76.9% for E2 at 12 month /25°C/60% RH).
Potency by Enzyme-Linked Immunosorbent Assay
Samples demonstrated potency determinations ranging from 82 — 126%. There did not
appear to be any trends in percent potency with respect to either formulation type or stability
time points /conditions.
Peptide Mapping
Peptide maps were reted in light of the identifications made by LC/MS. For
deamidation of asparagine at light chain site N33 or N35, no significant differences from
frozen reference standard were observed in ations stored at 5°C, even out to 12
. At room temperature (25°C / 60% RH), deamidation above background could be
detected in the pH 6.5 formulations (E3 and E6) at two months. Significant deamidation
(>2% increase versus reference) was observed in a endent manner after 12 months at
°C / 60% RH. Similar increases were observed after two months at 40°C / 75% RH, with a
clear dependence on pH, but with lent results in sorbitol and sucrose. Note that levels
of modification in reference standard measured by UV (6.1— 8.3%) were reasonably similar
to those measured for the parent material by LC/MS (3.0%).
ation of asparagine at heavy chain site N381 or N3 86 responded very
similarly to
the light chain deamidation site. No significant differences from frozen reference standard
were observed in formulations stored at 5°C, even out to 12 months. At room temperature
(25°C / 60% RH), ation above background could be detected in the pH 6.5
formulations (E3 and E6) at two . Significant deamidation (>2% increase versus
reference) was observed in a pH-dependent manner after 12 months at 25°C / 60% RH,
Similar increases were observed after two months at 40°C / 75% RH, with a clear
dependence on pH, but with equivalent results in sorbitol and sucrose. The levels of
modification in reference standard measured by UV (5.9 — 6.8%) were r to those
measured for the parent material by LC/MS (3.3%).
For deamidation of asparagine at heavy chain site N312, no icant differences
frozen reference standard were observed in the study overall. Even at the 25°C /
60% RH, 12 month and 40°C / 75% RH, two—month time points, the peak percentages
were not significantly different from the frozen reference standard. This may indicate that
this asparagine site is not susceptible to deamidation, or that additional species are
present at the migration times of the peak identified as modified asparagine, g the
deamidation response. In support of this theory, total N312 modification was somewhat
higher in reference standard by UV analysis (5.1 — 9.8%) than in the parent material by
LC/MS (28%). Because the succinimide form of the Asn/Asp intermediate was most
abundant in the LC/MS data, actual ation may simply be low (<1%) at
all time points.
Proline and lysine ylation, although present in significant nce in the
reformulated samples, did not appear to change with time, regardless of e temperature.
Hydroxylation of P189 was very consistent and unchanged at all time points. Interestingly,
this e hydroxylation was lower in the frozen reference standard. The levels of proline
hydroxylation in reference rd measured by UV (1.1— 1.6%) were reasonably r to
those measured by LC/MS (1.0%). Measurement of K121 hydroxylation produced much
larger differences in quantities. However, because no consistent trends could be observed, it
is concluded these differences represent ical noise. The levels of lysine hydroxylation
in reference standard measured by UV (4.1 — 7.9%) were reasonably similar to those
measured in the parent material by LC/MS (2.8%).
Methionine oxidation at heavy chain site M425 was fairly conducive to analysis.
Small, but consistent, levels of oxidation were seen in all formulations. Oxidation increased
slowly as a function of time and temperature, but was not affected by the pH or formulation
components. Even after two months at 40°C / 75% RH, the oxidation increased only by about
0.5%. The levels of ation in reference standard measured by UV (0.2 —0.6%) were
very similar to those measured in the parent material by LC/MS (0.3%).
Particle Count Micro-Flow Imaging)
Particle counting by MFI was performed only at the three-month time point. Overall, samples
ated with 250 mM sorbitol appeared to demonstrate lower particle counts at larger
particle sizes (10 um and 25 um). Among those s formulated in 250 mM sucrose,
formulation E2
appeared to demonstrate slightly lower particle counts overall. There did not appear to be a
significant difference in particle counts between ations at differing API concentration.
While the invention has been described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate and not limit the scope of the
ion, which is defined by the scope of the appended claims. Other aspects, advantages,
and modifications are within the scope of the following claims.
Claims (20)
1. A method of treating a thy in a human subject in need thereof, the method comprising intravenously administering to the human subject a fixed dose of 2000 mg of an anti—human tau antibody once every four weeks, wherein the anti-human tau antibody comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein: (a) the VH comprises VH complementarity determining regions Rs), wherein: VH—CDR] consists of the amino acid ce of SEQ ID NO:16, VH-CDR2 ts of the amino acid sequence of SEQ ID N017, and VH—CDR3 consists of the amino acid sequence of SEQ ID N018, and (b) the VL comprises VL-CDRs, wherein: VL—CDRl consists of the amino acid sequence of SEQ ID N0119; VL-CDR2 consists of the amino acid sequence of SEQ ID NO:20, and VL-CDR3 consists of the amino acid sequence of SEQ ID NO:21.
2. The method of claim 1, wherein the tauopathy is Alzheimer’s disease, amyotrophic lateral sclerosis/parkinsonism— dementia x, argyrophilic grain dementia, British type amyloid athy, cerebral amyloid angiopathy, corticobasal ration, Creutzfeldt— Jakob disease, dementia pugilistica, e neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, multiple system y, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian motor neuron disease with ibrillary tangles, Pick's e, cephalitic parkinsonism, prion protein cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, Tangle only dementia, multi-infarct dementia, stroke, chronic traumatic alopathy, traumatic brain injury, concussion, seizures, epilepsy, or acute lead encephalopathy.
3. The method of claim 1, wherein the tauopathy is progressive supranuclear palsy.
4. The method of claim 1, wherein the tauopathy is Alzheimer’s disease.
5. The method of any one of the ing claims, wherein the VH consists of SEQ ID NO: 12 and the VL consists of SEQ ID NO: 13.
6. The method of any one of the preceding claims, wherein the anti-human tau antibody comprises a heavy chain and a light chain, n the heavy chain consists of SEQ ID N014 and the light chain ts of SEQ ID NO:15.
7. A pharmaceutical composition comprising: (i) an anti-human tau antibody at a concentration of 50 mg/ml, (ii) histidine at a concentration of 20 mM, (iii) sucrose at a concentration of 250 mM, (iv) rbate—80 at a tration of 0.05% (w/v), and (v) 50 uM diethylenetriamine pentaacetic acid (DTPA) wherein the anti-human tau antibody ses an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein: (a) the VH comprises VH complementarity determining regions (VH-CDRs), wherein: VH-CDRI consists of the amino acid sequence of SEQ ID NO:16, VH-CDR2 consists of the amino acid sequence of SEQ ID N017; and VH—CDR3 consists of the amino acid sequence of SEQ ID N018; and (b) the VL comprises VL-CDRs, wherein: VL—CDRl consists of the amino acid sequence of SEQ ID NO:19, VL-CDRZ consists of the amino acid sequence of SEQ ID NO:20, and VL—CDR3 consists of the amino acid sequence of SEQ ID N021, and wherein the composition has a pH of 6.0.
8. The ceutical composition of claim 7, wherein the VH consists of SEQ ID N012 and the VL consists of SEQ ID NO:13.
9. The pharmaceutical composition of claim 7, wherein the anti-human tau antibody comprises a heavy chain and a light chain, wherein the heavy chain consists of SEQ ID N014 and the light chain consists of SEQ ID NO:15.
10. ‘ A method of ng a tauopathy in a human subject in need thereof, the method comprising intravenously administering to the human subject the pharmaceutical composition of any one of claims 7 to 9.
11. The method of claim 10, wherein the anti—human tau antibody is administered at a fixed dose of 150 mg once every four weeks.
12. The method of claim 10, wherein the anti-human tau antibody is administered at a fixed dose of 210 mg once every four weeks.
13. The method of claim 10, wherein the anti-human tau dy is administered at a fixed dose of 700 mg once every four weeks.
14. The method of claim 10, wherein the anti-human tau antibody is administered at a fixed dose of 2000 mg once every four weeks.
15. The method of claim 10, wherein the anti-human tau antibody is stered at a fixed dose of 2100 mg once every four weeks.
16. The method of claim 10, wherein the anti—human tau antibody is administered at a fixed dose of 4200 mg once every four weeks.
17. The method of any one of claims 11 to 16, wherein the ceutical ition is administered for at least 12 weeks.
18. The method of any one of claims 10 to 17, n the tauopathy is Alzheimer's disease, amyotrophic lateral sclerosis/parkinsonism— dementia complex, philic grain dementia, British type amyloid angiopathy, cerebral amyloid angiopathy, corticobasal degeneration, Creutzfeldt- Jakob disease, dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, frontotemporal dementia (FTD), frontotemporal dementia with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, Gerstmann-Straussler-Scheinker disease, vorden-Spatz disease, inclusion body myositis, multiple system atrophy, myotonic dystrophy, Niemann-Pick disease type C, non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, prion protein cerebral amyloid athy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sing panencephalitis, Tangle only dementia, multi- infarct dementia, stroke, chronic traumatic encephalopathy, traumatic brain injury, concussion, es, epilepsy, or acute lead encephalopathy.
19. The method of any one of claims 10 to 17, wherein the tauopathy is progressive supranuclear palsy.
20. The method of any one of claims 10 to 17, wherein the tauopathy is Alzheimer's disease. om com wmmmmeMHmEdammHMQGmmm0Mmm¢S IIIIIIIIIIIIIII IIIIIIIIIIIIIII Omfi owm Qom IIIIIIIIIIIIIII IIIIIIIIIIIIIII QNH UflflmomfimmHQwHwHmDm¢HmBmMflQmHmm ommmmmqmmaowmemmm wfimomgmmfiowHw/fimm mammomqmmaogwgmm ugmmmqmmfiogwfimm qufimHOGHOQOEEHNGGOQMMQGHGNHwflmQm2>mmm0¢mm< MdUflQHQUHOQOESBNUUODMmQUHUNHwflmDm2>mmMOMmmfl deflmHowMOQOEEBNOGODMmQGQOWBOmmm0Mmmfl defloHowHOQOEZEMGOOQMmQUHOwEwmmm0Mmmfl IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII lllllllllllllllllllllllllllllllllllllllll IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII Mmflmmemm1MHEm MEm MmflmmeMflmIfieflZflMOMOwmmflflUmMemHMMDQflOMflMMQQmewQMmMm>2m¢OH>m MmflmMHMflmHMBEm MflmmmmMmmHm>>fi>MMmHMBmmHmflmmHMmMmememwmmmwomeDmMmmflwmmmmH M>>¢>MMmfixammamdmmHMWmememmwmmmNDmMmeMmmmwwmmmH memewmmwmmmMOwMQOmMmmmwmmmmH MmQUMmO>ZmFQFMMZFHO>MwwmeEMéZEHmDFMmM>ZMHQmEm>m¢HOHMm HZQQmeMmO>MDMmQrM?mM>:>O®OO&MEEHZ©QmQOMmB>Mwafl>mmw>HO>mwwwm >ZQHmemm>ZmflmmmmBflwm>>mmMW>HEflDEQHM¢M¢memHQMEBEFMMZ©O©m>mB fivv moocmzmow M QO0M¢qmmQ
Publications (1)
Publication Number | Publication Date |
---|---|
NZ789385A true NZ789385A (en) | 2022-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220411486A1 (en) | Humanized Antibodies That Recognize Alpha-Synuclein | |
AU2017418317A1 (en) | Compositions and methods for treating tauopathies | |
US20200190178A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
TWI781507B (en) | Anti-transthyretin antibodies | |
TW201643197A (en) | Antibodies to TAU and uses thereof | |
US20200377579A1 (en) | Compositions and methods for treating synucleinopathies | |
CA2974993A1 (en) | Anti-transthyretin antibodies | |
CA3077361A1 (en) | Anti-transthyretin antibodies | |
KR20180081522A (en) | Binding agents for the treatment of nervous system and other disorders | |
US11702467B2 (en) | High affinity antibodies targeting tau phosphorylated at serine 413 | |
KR20230003187A (en) | Interleukin-34 targeting compounds and methods | |
NZ789385A (en) | Compositions and methods for treating tauopathies | |
US20190135905A1 (en) | Compositions and methods for treating tauopathies | |
JP2021502955A (en) | Administration regimen for the treatment of synuclein disease | |
EA039569B1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof |